Logo
x

Search

Subscribe Now

Antengene

Antengene Entered into a Commercialization Agreement with Hansoh Pharma for Xpovio (selinexor) in the Mainland of China

Antengene Entered into a Commercialization Agreement with Hansoh Pharma for Xpovio (selinexor) in the Mainland of China

  • August 11, 2023
Antengene Reports the First Patient Dosing in the P-I Trial (ERASER) of ATG-017 + Nivolumab for the Treatment of Advanced Solid Tumors

Antengene Reports the First Patient Dosing in the P-I Trial (ERASER) of ATG-017 + Nivolumab for the Treatment of Advanced Solid Tu...

  • July 18, 2023
Antengene Receives the US FDA’s IND Clearance of ATG-031 for Advanced Solid Tumors or B-Cell Non-Hodgkin's Lymphoma

Antengene Receives the US FDA’s IND Clearance of ATG-031 for Advanced Solid Tumors or B-Cell Non-Hodgkin's Lymphoma

  • May 18, 2023
Antengene Entered into a Clinical Collaboration with MSD to Evaluate ATG-037 + Keytruda (pembrolizumab) for Solid Tumors

Antengene Entered into a Clinical Collaboration with MSD to Evaluate ATG-037 + Keytruda (pembrolizumab) for Solid Tumors

  • December 27, 2022
Antengene Reports P-I/II (TORCH-2) Study Results of ATG-008 for the Treatment of Relapsed/Metastatic Cervical Cancer

Antengene Reports P-I/II (TORCH-2) Study Results of ATG-008 for the Treatment of Relapsed/Metastatic Cervical Cancer

  • November 16, 2022
Antengene Receives the US FDA’s IND Clearance of ATG-017 to Initiate P-I (ERASER) Trial for Advanced Solid Tumors

Antengene Receives the US FDA’s IND Clearance of ATG-017 to Initiate P-I (ERASER) Trial for Advanced Solid Tumors

  • November 1, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.